Citations 0
From the Food and Drug Administration
November 6, 2002

Adjuvant Breast Cancer Treatment

Author Affiliations

Not Available


Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002American Medical Association

Not Available

JAMA. 2002;288(17):2112. doi:10.1001/jama.288.17.2112-JFD20011-2-1

The FDA has approved anastrozole (Arimidex, AstraZeneca Pharmaceuticals LP, Wilmington, Del) for adjuvant treatment of postmenopausal women with hormone receptor–positive early breast cancer. The drug, a nonsteroidal aromatase inhibitor, had been approved for two indications in postmenopausal women, including first-line treatment of locally advanced or metastatic breast cancer and treatment of advanced breast cancer in women with disease progression following tamoxifen therapy.

First Page Preview View Large
First page PDF preview
First page PDF preview